Recurrent ovarian cancer: everolimus plus bevacizumab fails phase 2

  • Taylor SE & al.
  • Gynecol Oncol
  • 15 Nov 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Everolimus+bevacizumab fails to improve response rate vs historical response with bevacizumab alone in patients with recurrent ovarian, peritoneal, and fallopian tube cancer.
  • Long-term responders show alterations in the phosphoinositide 3-kinase (PI3K) pathway.

Why this matters

  • Recurrent ovarian cancer has poor prognosis and warrants novel therapeutic approaches.

Study design

  • Phase 2 study of 50 patients (median age, 60.5 years) with recurrent ovarian, peritoneal, and fallopian tube cancer.
  • Patients received oral everolimus daily and intravenous bevacizumab every 14 days on a 28-day cycle.
  • Funding: None disclosed.

Key results

  • Median number of treatment cycles completed: 4.
  • 24% of patients (adjusted) were progression-free at 6 months.
  • The adjusted median PFS was 3.67 months.
  • 76% of patients discontinued treatment due to disease progression.
  • 2.2% of patients achieved a complete response, 13.0% had a partial response, and 76.1% had stable disease.
  • 25 patients experienced a total of 31 grade 3 adverse events.
  • 2 grade 4 toxicities were reported.
  • Long-term responders with clear cell carcinomas had alterations in the PI3K pathway.

Limitations

  • Open-label design.